Mitochondria in Parkinson disease: back in fashion with a little help from genetics

Arch Neurol. 2006 May;63(5):649-54. doi: 10.1001/archneur.63.5.649.

Abstract

Parkinson disease is a devastating neurodegenerative disorder with no known cure. Impairment in mitochondrial dysfunction is thought to play a major role in the pathogenesis. Recent genetic advances suggest that mitochondrial dysfunction may be the primary defect. Drugs that target the mitochondria may therefore represent the best hope for disease-modifying therapies in Parkinson disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Intracellular Signaling Peptides and Proteins / genetics
  • Mitochondria / genetics
  • Mitochondria / pathology*
  • Mitochondrial Diseases* / complications
  • Mitochondrial Diseases* / genetics
  • Mitochondrial Diseases* / pathology
  • Models, Biological
  • Oncogene Proteins / genetics
  • Parkinson Disease / etiology
  • Parkinson Disease / genetics
  • Parkinson Disease / pathology*
  • Protein Deglycase DJ-1
  • Protein Kinases / genetics

Substances

  • Intracellular Signaling Peptides and Proteins
  • Oncogene Proteins
  • Protein Kinases
  • PTEN-induced putative kinase
  • PARK7 protein, human
  • Protein Deglycase DJ-1